Papaverine Hydrochloride
Phase 1Small molecule
Papaverine Hydrochloride is one of 18 small molecule programs targeting Lung Non-Small Cell Carcinoma. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Lung Non-Small Cell Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Tecentriq
RochePhase 3
Imfinzi
AstraZenecaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Gemzar
Johnson & JohnsonPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Paraplatin
AAvyxa
Phase 3
Taxotere
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy1 trial
The Efficacy of Papaverine to Prevent Radial Artery Spasm During Transradial Cerebral Angiography
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05861765·240 enrolled
Lung Non-Small Cell Carcinoma1 trial
A Phase I Trial Combining Papaverine and Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer or Lung Metastases
Active, not recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT03824327·19 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Papaverine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details